Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171257 · ClinicalTrials.gov registry record
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 197
- Enrollment target
NCT05171257 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 197 participants.
The verdict
NCT05171257 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 197 participants
- Enrollment target
Study Summary
Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeruginosa strain; however, the use of an agent with antipseudomonal activity would select for resistance to that particular antimicrobial agent or class. Demonstrated that each additional day of exposure to any antipseudomonal beta-lactam is associated with an increased risk of new resistance development. The study seeks to determine whether the choice of empiric therapy (i.e., the same agent versus a different agent from prior antibiotic exposure) has any effect on the likelihood of in vitro activity against GN pathogens (GNPs) in a subsequent infection.
Interventions
- DRUG IV antibiotic treatment from prior
- DRUG differing IV antibiotic treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2025-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171257
The ClinicalTrials.gov registry entry for NCT05171257 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV antibiotic treatment from prior is the first listed.
NCT05171257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05171257 about?
NCT05171257 is a clinical study titled "Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit". Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor. For example, the use of non-antipseudomonal agents can increase risk for any P. aeru...
What is the current status of trial NCT05171257?
This trial is currently completed. The enrollment target is 197 participants. The study started on 2021-10-19. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT05171257?
The interventions under investigation include: IV antibiotic treatment from prior (DRUG), differing IV antibiotic treatment (DRUG).
Who is sponsoring clinical trial NCT05171257?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.